1.
Pittella C. [Impact of the Subcutaneous Formulation of Daratumumab in the Treatment of Multiple Myeloma: pharmacoeconomic aspects of the new formulation]. FE. 2026;27(1):81-90. doi:10.7175/fe.v27i1.1615